Proposal provides welcome certainty for NAC but leaves fundamental questions about dietary supplement innovation unresolved
WASHINGTON — The Council for Responsible Nutrition (CRN), the leading trade association representing the dietary supplement and functional food industry, today welcomed the U.S. Food and Drug Administration's (FDA) proposed rule that would allow N-acetyl-L-cysteine (NAC) to be lawfully marketed in dietary supplements. However, CRN emphasized that the proposal falls short of providing a predictable process for other ingredients to be added to the list and leaves broader questions about the drug preclusion framework unresolved.
The proposal is a positive step toward resolving the longstanding regulatory uncertainty surrounding NAC; but it does not resolve the fundamental questions about when and how drug preclusion applies—questions that extend well beyond NAC. The proposed rule demonstrates the need for corrective legislation like the Dietary Supplement Innovation Act to provide a clear roadmap for drug preclusion.
"We welcome FDA's proposal to establish a regulatory pathway that would provide certainty for NAC," said Steve Mister, president and CEO of CRN. "But without a clear framework for how other ingredients can be added, the industry is left with many of the same uncertainties that have persisted for years.
Mister continued: "Drug preclusion is essentially a convergence of pharmaceutical and supplement economic interests; safety is only one factor in the decision. We need clear, transparent and predictable criteria for when drug preclusion applies that provide certainty not just for NAC, but for dietary supplement innovation more broadly."
CRN's May 2023 citizen petition and March 2025 supplemental submission urged FDA to reconsider its interpretation of the drug preclusion provision under Section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act. Among other requests, CRN called on FDA to establish clear criteria for exercising its statutory authority to permit certain ingredients to be marketed as dietary supplements, even when they might otherwise be subject to drug preclusion. CRN cautioned then that failing to give clear direction “only serves to ‘kick the can down the road’ and to avoid addressing critical questions.” FDA’s narrow response for NAC does that again today.
While FDA denied CRN's petition in September 2025, the proposed rule reflects some of the concerns CRN has consistently raised regarding the need for a more predictable approach to drug preclusion. As CRN stated in its 2023 petition, FDA’s failure to provide clarity to industry about the application of section 201(ff)(3)(B) creates continued unpredictability for the supplement industry, dissuades innovation, and limits consumer access.
"FDA has opened the door for other ingredients to be considered, but it has not explained how manufacturers can walk through it," Mister said.
CRN emphasized that broader reform must address fundamental questions regarding when drug preclusion applies, including FDA's reliance on confidential investigational new drug application dates, the meaning of substantial clinical investigations, and the circumstances under which pharmaceutical research should preclude an ingredient from the dietary supplement marketplace. Drug preclusion decisions must account for the competing interests of pharmaceutical and dietary supplement manufacturers, including whether products differ in their routes of administration, dosage levels and intended uses. These distinctions are essential to determining whether the products genuinely compete in the marketplace and whether excluding an ingredient from dietary supplements serves the purposes of the law.
CRN reiterates its support for the Dietary Supplement Innovation Act, H.R. 10336, introduced by Rep. Diana Harshbarger, which would modernize the statutory framework, establish more transparent standards and preserve appropriate incentives for pharmaceutical innovation without unnecessarily restricting access to dietary supplements.
CRN will carefully evaluate the proposed rule and provide comments, while continuing to advocate for broader reforms that bring transparency, fairness and predictability to the drug preclusion framework.
###
The Council for Responsible Nutrition (CRN), founded in 1973 and based in Washington, D.C., is the leading trade association representing the dietary supplement and functional food industry. Bringing together manufacturers, ingredient suppliers, and service providers, CRN unites its member companies around a shared commitment to science, transparency, and responsible business practices—advancing a strong, credible marketplace that supports consumer health and industry growth.
In an increasingly complex regulatory and media environment, CRN serves as the industry’s front line—shaping science-based policy, defending market access, and countering misinformation. Through strategic advocacy, self-regulatory leadership, voluntary guidelines, and evidence-based communications, CRN ensures that responsible companies are recognized, protected, and positioned to innovate and compete. Learn more at crnusa.org and follow @CRN_Supplements on X and LinkedIn.
